Schaffler K, Klausnitzer W
Institute for Pharmacodynamic Research, Munich, Fed. Rep. of Germany.
Arzneimittelforschung. 1988 Feb;38(2):288-91.
The effects of two acute doses (1600 mg, 2400 mg) of 2-oxo-pyrrolidine-1-acetamide (piracetam, Normabraïn) on hypoxia resistance were screened vs placebo in a randomized, double-blind 3-way change-over design in 9 healthy male volunteers (mean age: 26.4 +/- 3.5 years; mean body weight: 74.9 +/- 8.4 kg). Psychophysiological measurements were done with the oculodynamic test (ODT) for oculomotor, performatory and additional cardiorespiratory parameters. Intradiurnal assessments were done under normoxia (prevalue) and hypoxic hypoxidosis (1 hypoxic prevalue, 3 postdose values: 1.0, 2.5 and 4.0 h) with a content of 10.5% O2 and 89.5% N2 in inspired air (hypoxic hypoxidosis)--as a model of brain dysfunctions, related with several types of senile dementia (Primary Degenerative Dementia = Alzheimer type; Multi Infarct Dementia). The results indicate that piracetam especially in its higher dose (2400 mg) displays antihypoxidotic effects already after a single administration in oculomotor, performatory and cardiorespiratory parameters.
在9名健康男性志愿者（平均年龄：26.4±3.5岁；平均体重：74.9±8.4 kg）中，采用随机、双盲、三向交叉设计，将两种急性剂量（1600毫克、2400毫克）的2-氧代吡咯烷-1-乙酰胺（吡拉西坦，脑复康）与安慰剂进行对比，以筛选其对缺氧耐受性的影响。通过眼动力测试（ODT）对眼动、行为表现及其他心肺参数进行心理生理学测量。在常氧（预值）和低氧低氧血症（1个低氧预值、3个给药后值：1.0、2.5和4.0小时）条件下进行日内评估，吸入空气中氧气含量为10.5%，氮气含量为89.5%（低氧低氧血症）——作为与几种类型的老年痴呆（原发性退行性痴呆=阿尔茨海默型；多发梗死性痴呆）相关的脑功能障碍模型。结果表明，吡拉西坦尤其是高剂量（2400毫克）在单次给药后，在眼动、行为表现和心肺参数方面已显示出抗低氧血症作用。
